Siga Technologies INC Excess Tax Benefit from Share-based Compensation, Financing Activities
Siga Technologies INC (SIGA) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-06.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2015-03-06
- Siga Technologies INC excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- Siga Technologies INC excess tax benefit from share-based compensation, financing activities for fiscal 2013 was $23.67K.
- Siga Technologies INC excess tax benefit from share-based compensation, financing activities for fiscal 2012 was $0.00.
- Siga Technologies INC excess tax benefit from share-based compensation, financing activities for fiscal 2011 was $0.00.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|
| 2014-12-31 | $0.00 10-K · filed 2015-03-06 |
| 2013-12-31 | $23.67K 10-K · filed 2015-03-06 |
| 2012-12-31 | $0.00 10-K · filed 2015-03-06 |
| 2011-12-31 | $0.00 10-K · filed 2014-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |